FDA 执法报告 D-0082-2027:Par Health USA 阿加曲班注射液因颗粒物召回列为 Class I
FDA drug enforcement D-0082-2027: Par Health USA, LLC — Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
FDA 执法报告 D-0082-2027 将 Par Health USA 主动召回的阿加曲班注射液(100 mg/mL,2.5 mL 单剂量瓶)列为 Class I,涉及 18,991 瓶并在美国全国分销。
记录列出涉事批号、有效期、分销范围与颗粒物类型,可帮助核对本次召回的产品边界与 Class I 分级信息。
FDA 药品召回执法报告 — D-0082-2027
报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归集多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所对应的含义。
完整官方产品记录(含 openFDA 统一标识符):
{
"address_1": "870 Parkdale Rd",
"address_2": "",
"center_classification_date": "20261026",
"city": "Rochester",
"classification": "Class I",
"code_info": "Lot #: 83449, Exp Date: 10/2026; 82682, Exp Date: 11/2026; 86714, 87302, 87560, Exp Date: 02/2027; 87753, 88401, Exp Date: 03/2027; 88614, 88836, Exp Date: 04/2027; 90220, Exp Date: 05/2027; 91216, 91219, Exp Date: 06/2027; 92004, 92006, Exp Date: 07/2027; 92009, 92596, 92782, 93107, 93329, Exp Date: 08/2027; 93890, Exp Date: 09/2027.",
"country": "United States",
"distribution_pattern": "Nationwide within the United States",
"event_id": "100072",
"initial_firm_notification": "Press Release",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA091665"
],
"brand_name": [
"ARGATROBAN"
],
"generic_name": [
"ARGATROBAN"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Par Health USA, LLC"
],
"nui": [
"N0000175980",
"N0000175518",
"N0000009963"
],
"package_ndc": [
"42023-182-01"
],
"pharm_class_epc": [
"Anti-coagulant [EPC]",
"Direct Thrombin Inhibitor [EPC]"
],
"pharm_class_moa": [
"Thrombin Inhibitors [MoA]"
],
"product_ndc": [
"42023-182"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"INTRAVENOUS"
],
"rxcui": [
"308351"
],
"spl_id": [
"05c8d32d-744b-4758-a94e-d912f410bbf7"
],
"spl_set_id": [
"d4e5238f-2378-424e-bda2-f1a2cf874041"
],
"substance_name": [
"ARGATROBAN"
],
"unii": [
"IY90U61Z3S"
]
},
"postal_code": "48307-1740",
"product_description": "Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-182-01.",
"product_quantity": "18,991 vials",
"product_type": "Drugs",
"reason_for_recall": "Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.",
"recall_initiation_date": "20261013",
"recall_number": "D-0082-2027",
"recalling_firm": "Par Health USA, LLC",
"report_date": "20261028",
"state": "MI",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov